Leslie Citrome, MD, MPH
Clinical Professor, Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York, and has a private practice in Pomona, New York. He also is a member of the Board of Directors of the American Society of Clinical Psychopharmacology. Dr. Citrome spent nearly two decades as a researcher in psychopharmacological treatment of severe mental disorders, including the management of treatment-refractory schizophrenia, and the management of aggressive and violent behavior.

Dr. Citrome is the Editor-in-Chief of the International Journal of Clinical Practice, and is the author or co-author of more than 400 published research reports, reviews, book chapters, and books in the biomedical literature. He has lectured extensively throughout the United States, Canada, Europe, and Asia.

Megan J. Ehret, PharmD, MS, BCPP
Associate Professor 
Department of Pharmacy Practice and Science 
University of Maryland, School of Pharmacy
Baltimore, Maryland

Dr. Ehret is a graduate of the University of Toledo where she completed her BS and PharmD degrees, and she went on to complete a Psychiatric Pharmacy Residency at the Louis Stokes VAMC, under the direction of Matthew Fuller.  She then completed a Psychopharmacology and Pharmacogenomics Fellowship at Nova Southeastern University, under the direction of Gary Levin.  She is the current Past-President for the College of Psychiatric and Neurologic Pharmacists Association. Her full-time role is an Associate Professor at the University of Maryland School of Pharmacy with a practice site at The University of Maryland Mid Town Campus.  She is currently Chair of the Student Affairs Committee.  Additionally, she also has the privilege of working with the State of Maryland Medicaid Program in evaluating antipsychotic use in the state Dr. Ehret has numerous publications and book chapters describing psychotropic medication adherence and the role of pharmacogenomics in medication selection.   Her current interests include psychotropic medication adherence and the advancement of the psychiatric pharmacist in practice.

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine. 

Faculty
Leslie Citrome, MD, MPH–has disclosed that he is a consultant for Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, and Vanda. He receives royalties from Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics. He is also a member of the speakers’ bureau for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, and Teva.
Megan J. Ehret, PharmD, MS, BCPP––has no relevant financial relationships to disclose in relation to the content of this activity.

Content Reviewers
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.